Drug Profile
Research programme: SMTP - TMS
Alternative Names: SMTPLatest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator TMS
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors; Plasminogen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Inflammation; Metabolic disorders
Most Recent Events
- 13 Sep 2023 Preclinical development is ongoing for Cancer (unspecified route) in Japan (TMS pipeline, September 2023)
- 13 Sep 2023 Preclinical development is ongoing for Inflammation in Japan (unspecified route) (TMS pipeline, September 2023)
- 13 Sep 2023 Preclinical development is ongoing for Metabolic disorders in Japan (unspecified route) (TMS pipeline, September 2023)